CJC-1295 with DAC: hormone results versus fitness claims

CJC-1295 with DAC is a long-acting analogue of growth hormone–releasing hormone. Its drug-affinity complex binds to albumin after injection, keeping it in circulation for days. CJC without DAC, often called modified GRF (1–29), is a different molecule and should not inherit its study results or schedules. [1–3]

What has been shown in people?

Two randomized, placebo-controlled dose-escalation studies in healthy adults measured hormone responses over 28 and 49 days. After a single CJC-1295 dose, average growth-hormone levels were about two to ten times baseline for at least six days; IGF-1 rose about 1.5 to three times baseline for nine to eleven days. The estimated half-life was roughly six to eight days. [1]

A smaller physiology study found that overnight growth-hormone pulses persisted a week after injection, alongside higher baseline hormone levels. Neither study was designed to show bigger muscles, fat loss, injury recovery, better sleep, or longer life. A measured hormone rise should not be presented as those outcomes. [1,2]

What are the limits and risks?

The published healthy-adult exposure was brief. FDA's review notes uncertainty about the precise drug substance and long-term safety, plus possible immune responses to injected peptide products. Sustained IGF-1 exposure may matter clinically for people with endocrine or other health conditions. The small trials cannot rule out uncommon harms. [1,3]